95 related articles for article (PubMed ID: 12036921)
1. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.
Bertolini F; Dell'Agnola C; Mancuso P; Rabascio C; Burlini A; Monestiroli S; Gobbi A; Pruneri G; Martinelli G
Cancer Res; 2002 Jun; 62(11):3106-12. PubMed ID: 12036921
[TBL] [Abstract][Full Text] [Related]
2. Expression of Concern: Human Anti-CXCR4 Antibodies Undergo VH Replacement, Exhibit Functional V-Region Sulfation, and Define CXCR4 Antigenic Heterogeneity.
Xu C; Sui J; Tao H; Zhu Q; Marasco WA
J Immunol; 2024 Jun; 212(11):1855. PubMed ID: 38768411
[No Abstract] [Full Text] [Related]
3. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
4. The intricate role of CXCR4 in cancer.
Chatterjee S; Behnam Azad B; Nimmagadda S
Adv Cancer Res; 2014; 124():31-82. PubMed ID: 25287686
[TBL] [Abstract][Full Text] [Related]
5. The significance of cancer cell expression of the chemokine receptor CXCR4.
Balkwill F
Semin Cancer Biol; 2004 Jun; 14(3):171-9. PubMed ID: 15246052
[TBL] [Abstract][Full Text] [Related]
6. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Caracciolo D; Mancuso A; Polerà N; Froio C; D'Aquino G; Riillo C; Tagliaferri P; Tassone P
Exp Hematol Oncol; 2023 Jan; 12(1):5. PubMed ID: 36624522
[TBL] [Abstract][Full Text] [Related]
7. Aberrant regulation of CXCR4 in cancer via deviant microRNA-targeted interactions.
Stuckel AJ; Khare T; Bissonnette M; Khare S
Epigenetics; 2022 Dec; 17(13):2318-2331. PubMed ID: 36047714
[TBL] [Abstract][Full Text] [Related]
8. Enhanced CXCR4 Expression of Human CD8
Burkard T; Dreis C; Herrero San Juan M; Huhn M; Weigert A; Pfeilschifter JM; Radeke HH
Front Immunol; 2021; 12():668884. PubMed ID: 34504486
[TBL] [Abstract][Full Text] [Related]
9. Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.
Kang TG; Park HJ; Moon J; Lee JH; Ha SJ
Immune Netw; 2021 Jun; 21(3):e23. PubMed ID: 34277113
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal.
Ottaiano A; Santorsola M; Del Prete P; Perri F; Scala S; Caraglia M; Nasti G
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209026
[No Abstract] [Full Text] [Related]
11. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.
Valle-Argos B; Chiodin G; Bryant DJ; Taylor J; Lemm E; Duriez PJ; Rock PJ; Strefford JC; Forconi F; Burack RW; Packham G; Stevenson FK
Sci Rep; 2021 Jun; 11(1):11676. PubMed ID: 34083646
[TBL] [Abstract][Full Text] [Related]
12. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.
Midavaine É; Côté J; Sarret P
Cancer Metastasis Rev; 2021 Jun; 40(2):427-445. PubMed ID: 33973098
[TBL] [Abstract][Full Text] [Related]
13. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.
Liu G; Rui W; Zhao X; Lin X
Cell Mol Immunol; 2021 May; 18(5):1085-1095. PubMed ID: 33785843
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells.
Chien YC; Chen JN; Chen YH; Chou RH; Lee HC; Yu YL
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635336
[TBL] [Abstract][Full Text] [Related]
15. Enhanced CXCR4 Expression Associates with Increased Gene Body 5-Hydroxymethylcytosine Modification but not Decreased Promoter Methylation in Colorectal Cancer.
Stuckel AJ; Zhang W; Zhang X; Zeng S; Dougherty U; Mustafi R; Zhang Q; Perreand E; Khare T; Joshi T; West-Szymanski DC; Bissonnette M; Khare S
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110952
[TBL] [Abstract][Full Text] [Related]
16. Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma.
Tamayo-Orbegozo E; Amo L; Díez-García J; Amutio E; Riñón M; Alonso M; Arana P; Maruri N; Larrucea S
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32046309
[TBL] [Abstract][Full Text] [Related]
17. Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells.
Ge X; Zhao Y; Chen C; Wang J; Sun L
Onco Targets Ther; 2019; 12():11033-11044. PubMed ID: 31997881
[TBL] [Abstract][Full Text] [Related]
18. Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M; Bueno D; González-Navarro P; Brito A; Fernández L; Escudero A; Valentín J; Mestre-Durán C; Arranz-Álvarez M; Pérez de Diego R; Mendiola M; Pozo-Kreilinger JJ; Pérez-Martínez A
Front Immunol; 2019; 10():1814. PubMed ID: 31428099
[TBL] [Abstract][Full Text] [Related]
19. Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring.
Lin Y; Lin Y; Lin X; Sun X; Luo K
J Cancer; 2019; 10(15):3420-3426. PubMed ID: 31293645
[TBL] [Abstract][Full Text] [Related]
20. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
